Repotrectinib & Capivasertib
from OncoPharm Hosted by John Bossaer
FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 23 minutes long.
When was this OncoPharm episode published?
This episode was published on November 23, 2023.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.